Overview

Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Insulin resistant states are characterized by hepatic lipoprotein (VLDL) particle overproduction. Numerous hormonal and nutritional factors are known to influence hepatic lipoprotein particle production, including insulin and free fatty acids (FFA). In contrast to the liver, the intestine has traditionally been viewed as a 'passive' organ with respect to lipoprotein production, with intestinal lipoprotein particle production determined mainly by the amount of fat ingested and absorbed. Glucagon plays a key role in the regulation of carbohydrate and fatty acid metabolism and has recently been shown for the first time to regulate hepatic lipoprotein production in mice. Ours will be the first study to investigate the effect of glucagon on hepatic and intestinal lipoprotein production in humans.
Phase:
Phase 4
Details
Lead Sponsor:
University Health Network, Toronto
Treatments:
Glucagon
Glucagon-Like Peptide 1